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To the Editor,
Large scale multi-omics analysis has identified signifi-
cant differences in the biomarkers between COVID-19 
disease and control subjects [1]. These protein panels tar-
get biological processes involved in vessel damage, plate-
let degranulation, the coagulation cascade and the acute 
phase response [1], with greater protein changes depend-
ent on the COVID-19 severity. However, it is observed 
that in metabolic conditions such as polycystic ovary 
syndrome expressed proteins differ compared to control 
women [2] and PCOS patients have increased platelet 
aggregation and decreased plasma fibrinolytic activity, 
resulting in a prothrombotic propensity [3, 4], with ele-
vated coagulation markers [5]. Therefore, any biomark-
ers reflecting COVID-19 disease and its severity would 
necessarily have to be independent of differentially-
expressed proteins relating to other conditions; therefore, 
this proteomic analysis was undertaken in women with 
and without PCOS to compare with the proteomic bio-
markers recently described in COVID-19 using shotgun 
proteomics followed by parallel reaction monitoring [1].
146 PCOS and 97 control women who presented 
sequentially to the Department of Endocrinology, Hull 
and East Yorkshire Hospitals NHS Trust were recruited 
to the local PCOS biobank (ISRCTN70196169) [2]. PCOS 
diagnosis was based on all three Rotterdam consensus 
diagnostic criteria. Proteins that were identified as being 
altered in COVID-19 disease for vessel damage (16 pro-
teins), platelet degranulation (11 proteins), coagula-
tion cascade (24 proteins) and acute phase response (9 
proteins), shown in Table  1, were determined by Slow 
Off-rate Modified Aptamer (SOMA)-scan plasma pro-
tein measurement [6]. Statistics were performed using 
Graphpad Prism 8.0.
As reported previously [2], cohorts were age-matched, 
but PCOS women had increased insulin resistance, 
androgens and CRP (p < 0.001): systolic and diastolic 
blood pressure, and waist circumference were higher 
(p < 0.05).
For the 60 protein biomarkers described previously, 21 
were found to differ in PCOS: for vessel damage 7 of 16 
proteins differed, for platelet degranulation 2 of 11 pro-
teins differed, for the coagulation cascade 9 of 24 proteins 
differed and for the acute phase response 3 of 9 proteins 
differed (Table 1).
These data show that altered protein expression relative 
to controls may occur in other conditions such as PCOS, 
and that COVID-19 biomarker changes found between 
respiratory patients with and without COVID-19 require 
validation before they can be confirmed to be related to 
COVID-19 disease and its severity. It is of concern that 
a number of significant protein biomarkers described 
for COVID-19 patients and its severity were also found 
in PCOS, spanning the biological processes involved in 
vessel damage, platelet degranulation, the coagulation 
cascade and the acute phase response, perhaps indicating 
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Table 1 Proteins identified as being altered in COVID-19 disease categorized according to biological processes: vessel damage (16 
proteins), platelet degranulation (11 proteins), coagulation cascade (24 proteins) and acute phase response (9 proteins) in PCOS and 
control women
Target full name Target UniProt Entrez gene ID Entrez gene symbol T-test PCOS 
vs control
Vessel damage
 Angiotensinogen Angiotensinogen P01019 183 AGT 0.0240
 Angiopoietin-1 Angiopoietin-1 Q15389 284 ANGPT1 0.0760
 Angiogenin Angiogenin P03950 283 ANG 0.2540
 EGF-containing fibulin-like extra-
cellular matrix protein 1
FBLN3 Q12805 2202 EFEMP1 0.4220
 Gelsolin Gelsolin P06396 2934 GSN 0.0002
 Hemopexin Hemopexin P02790 3263 HPX 0.4390
 Inter-alpha-trypsin inhibitor heavy 
chain H4
ITI heavy chain H4 Q14624 3700 ITIH4 0.5360
 Lumican Lumican P51884 4060 LUM 0.3790
 Nidogen-1 Nidogen P14543 4811 NID1 0.9600
 Neuropilin-1 NRP1 O14786 8829 NRP1 0.0090
 Periostin Periostin Q15063 10631 POSTN 0.0490
 Ras-related C3 botulinum toxin 
substrate 1
RAC1 P63000 5879 RAC1 0.5850
 Kallistatin Kallistatin P29622 5267 SERPINA4 0.0006
 Pigment epithelium-derived factor PEDF P36955 5176 SERPINF1 0.00003
 Transforming growth factor-beta-
induced protein ig-h3
BGH3 Q15582 7045 TGFBI 0.9890
 Tenascin Tenascin P24821 3371 TNC 0.0020
 Vitronectin Vitronectin P04004 7448 VTN 0.3930
Platelet degranulation
 Alpha-2-macroglobulin a2-Macroglobulin P01023 2 A2M 0.2660
 Clusterin Clusterin P10909 1191 CLU 0.6900
 Fibronectin Fibronectin P02751 2335 FN1 0.0098
 Platelet glycoprotein Ib alpha 
chain
GP1BA P07359 2811 GP1BA 0.1560
 Histidine-rich glycoprotein HRG P04196 3273 HRG 0.5890
 Integrin alpha-IIb: beta-3 complex gpIIbIIIa P08514 P05106 3674 3690 ITGA2B ITGB3 0.8370
 Neutrophil-activating peptide 2 NAP-2 P02775 5473 PPBP 0.2740
 Plasma serine protease inhibitor PCI P05154 5104 SERPINA5 0.0380
 Corticosteroid-binding globulin CBG P08185 866 SERPINA6 0.1790
 Thyroxine-binding globulin Thyroxine-Binding Globulin P05543 6906 SERPINA7 0.5730
 Transgelin-2 Transgelin-2 P37802 8407 TAGLN2 0.8690
 von Willebrand factor vWF P04275 7450 VWF 0.0770
Coagulation cascade
 Carboxypeptidase B2 TAFI Q96IY4 1361 CPB2 0.0170
 Prothrombin Prothrombin P00734 2147 F2 0.0920
 Coagulation Factor V Coagulation Factor V P12259 2153 F5 0.3020
 Coagulation factor VII Coagulation Factor VII P08709 2155 F7 0.2520
 Coagulation factor IX Coagulation Factor IX P00740 2158 F9  < 0.00001
 Coagulation factor Xa Coagulation Factor Xa P00742 2159 F10 0.1620
 Coagulation Factor XI Coagulation Factor XI P03951 2160 F11 0.5190
 Fibrinogen Fibrinogen P02671 P02675 P02679 2243 2244 2266 FGA FGB FGG 0.0126
 D-dimer D-dimer P02671 P02675 P02679 2243 2244 2266 FGA FGB FGG 0.00002
 Fibrinogen gamma chain Fibrinogen g-chain dimer P02679 2266 FGG 0.00002
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Limitations of the study include utilizing a different 
method of proteomic analysis compared to others that 
may not be directly comparable [1].
In conclusion, 21 of 60 protein biomarkers reported 
in respiratory patients with COVID-19 were found to 
differ between women with and without PCOS, show-
ing the necessity for validation of such biomarkers, and 
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Table 1 (continued)
Target full name Target UniProt Entrez gene ID Entrez gene symbol T-test PCOS 
vs control
 Hepatocyte growth factor activa-
tor
HGFA Q04756 3083 HGFAC 0.0830
 Plasma kallikrein Prekallikrein P03952 3818 KLKB1 0.0015
 Kininogen-1 Kininogen, HMW P01042 3827 KNG1 0.7970
 Plasminogen Plasminogen P00747 5340 PLG 0.6740
 Vitamin K-dependent protein S Protein S P07225 5627 PROS1 0.00003
 Vitamin K-dependent protein C Protein C P04070 5624 PROC 0.5110
 Alpha-1-antitrypsin a1-Antitrypsin P01009 5265 SERPINA1 0.1500
 Protein Z-dependent protease 
inhibitor
protein Z inhibitor Q9UK55 51156 SERPINA10 0.1720
 Antithrombin-III Antithrombin III P01008 462 SERPINC1 0.0003
 Heparin cofactor 2 Heparin cofactor II P05546 3053 SERPIND1 0.00003
 Plasminogen activator inhibitor 1 PAI-1 P05121 5054 SERPINE1 0.1680
 Alpha-2-antiplasmin a2-Antiplasmin P08697 5345 SERPINF2
Acute phase response
 Serum albumin Albumin P02768 213 ALB 0.0660
 Macrophage mannose receptor 1 Macrophage mannose receptor P22897 4360 MRC1 0.0020
 Hepatocyte growth factor-like 
protein
MSP P26927 4485 MST1 0.7340
 Protein S100-A9 calgranulin B P06702 6280 S100A9 0.0156
 Serum amyloid A-1 protein SAA P0DJI8 6288 SAA1 0.5095
 Alpha-1-antichymotrypsin a1-Antichymotrypsin P01011 12 SERPINA3 0.2672
 Superoxide dismutase [Cu–Zn] SOD P00441 6647 SOD1 0.9448
 Serotransferrin Transferrin P02787 7018 TF 0.0185
 Transketolase Transketolase P29401 7086 TKT 0.8309
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